Search

Sean M Marrache

age ~39

from Concord, CA

Get Report
Related to:
Connected to:

Sean Marrache Phones & Addresses

  • Concord, CA
  • Oakland, CA
  • 7247 N Fiske Ave, Portland, OR 97203
  • Beaverton, OR
  • Athens, GA
  • Marietta, GA

Work

  • Company:
    The university of georgia
    2010
  • Position:
    Graduate research assistant

Education

  • School / High School:
    The University of Georgia- Athens, GA
    2009
  • Specialities:
    Ph.D. in Bio-Organic / Polymer Chemistry

Skills

Organic and Polymer Synthesis Small Mol... • growth and differentiation Dendritic ce...

Resumes

Sean Marrache Photo 1

Sean Marrache Athens, GA

view source
Work:
The University of Georgia

2010 to 2000
Graduate Research Assistant The University of Georgia

2010 to 2000
Student Mentor The University of Georgia
Athens, GA
2009 to 2011
Teaching Assistant The University of Georgia
Athens, GA
2009 to 2010
Graduate Research Assistant The University of Georgia
Athens, GA
Mar 2009 to May 2009
Undergraduate Research Assistant
Education:
The University of Georgia
Athens, GA
2009 to 2014
Ph.D. in Bio-Organic / Polymer Chemistry The University of Georgia
Athens, GA
2004 to 2009
B.S. in Chemistry
Skills:
Organic and Polymer Synthesis Small Molecule synthesis and purification Ring-opening polymerization of poly(lactides) Atom-transfer radical-polymerization Polymer end-group functionalization Tissue Culture Cancer cell growth and maintenance Stem cell growth and differentiation Macrophage isolation, growth and differentiation Dendritic cell isolation Nanoparticle Synthesis Nanoprecipitation of polymeric nanoparticles Double and single emulsion of polymeric nanoparticles Gold nanoparticle synthesis and functionalization Super paramagnetic iron oxide nanoparticle synthesis and characterization Film rehydration self-assembled liposomes and polymeric nanoparticles Lipid-hybrid nanoparticles Drug loading determination Nanoparticle-drug release kinetic analysis Surface modification and functionalization Biological Assays and Experimentation Organelle isolation Mitochondrial subfractionation Nuclear and mitochondrial DNA isolation Cytotoxicity assays Flow cytometry Confocal and fluorescent microscopy Transmission Electron microscopy Protein quantification Immunological Assays Enzyme-linked immunosorbent assay (ELISA assays) Dendritic cell maturation T-cell proliferation In vivo Evaluation of Therapeutics and Delivery Vehicles Pharmacokinetic analysis Biodistribution Blood plasma cholesterol and triglyceride quantification

Us Patents

  • Mitochondria-Targeting Platinum(Iv) Prodrug

    view source
  • US Patent:
    20180066004, Mar 8, 2018
  • Filed:
    Apr 8, 2015
  • Appl. No.:
    15/302549
  • Inventors:
    - Athens GA, US
    Rakesh Pathak - Columbus OH, US
    Sean Marrache - Portland OR, US
  • Assignee:
    University of Georgia Research Foundation, Inc. - Athens GA
  • International Classification:
    C07F 15/00
  • Abstract:
    Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer.

  • Nanoparticles For Lipid Homeostasis

    view source
  • US Patent:
    20170367989, Dec 28, 2017
  • Filed:
    Dec 22, 2015
  • Appl. No.:
    15/536832
  • Inventors:
    Shanta DHAR - Miami FL, US
    Sean MARRACHE - Portland OR, US
    Ru WEN - Athens GA, US
    Bhabatosh BANIK - Athens GA, US
    - Athens GA, US
  • International Classification:
    A61K 9/51
    A61K 49/18
    A61K 9/28
    A61K 47/69
    A61K 9/127
    A61K 47/54
    B82Y 5/00
    A61K 45/06
  • Abstract:
    Nanoparticles include a polymeric core and a high density lipoprotein (HDL) component where the ratio by weight of the HDL component to the polymeric core is in a range from about 1:9 to about 9:1, such as about 75:25 or less or about 7:3 or less. The nanoparticles may also include a mitochondria targeting moiety. The nanoparticles may be used to treat or prevent atherosclerosis or to maintain lipid homeostasis.

  • Therapeutic Nanoparticles For Accumulation In The Brain

    view source
  • US Patent:
    20170216219, Aug 3, 2017
  • Filed:
    Aug 3, 2015
  • Appl. No.:
    15/501022
  • Inventors:
    - Athens GA, US
    Emily Wyatt Baker - Athens GA, US
    Sean Marrache - Portland OR, US
    Franklin D. West - Bogart GA, US
  • International Classification:
    A61K 9/51
    A61K 47/02
    A61K 31/573
    A61K 49/00
    A61K 9/00
    A61K 31/122
  • Abstract:
    Nanoparticles containing a mitochondrial that are capable of crossing the blood-brain barrier and that have a targeting moiety, an antioxidant and an anti-inflammatory agent may be useful for treatment of traumatic brain injury.

  • Mitochondrial Delivery Of 3-Bromopyruvate

    view source
  • US Patent:
    20170014361, Jan 19, 2017
  • Filed:
    Mar 13, 2015
  • Appl. No.:
    15/123786
  • Inventors:
    - Athens GA, US
    Sean Marrache - Portland OR, US
  • International Classification:
    A61K 31/19
    A61K 41/00
    A61N 5/06
    A61K 47/48
  • Abstract:
    A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-bromopyruvate (3-BP) and delocalized lipophilic triphenylphosphonium (TPP) cations to target the mitochondrial membrane potential (Δψm) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher Δψm in cancer cell compared to normal cells. This construct showed remarkable anticancer activity in prostate cancer cells compared to non-targeted construct NT-3-BP-AuNP and free 3-BP. Anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. T-3-BP-AuNPs showed markedly enhanced ability to alter cancer cell metabolism by inhibiting glycolysis and demolishing mitochondrial oxidative phosphorylation in prostate cancer cells. Our findings demonstrated that mitochondria targeted and concerted chemo-photothermal treatment of glycolytic cancer cells with a single NP may have promise as a new anticancer therapy.

  • Nanoparticles For Mitochondrial Trafficking Of Agents

    view source
  • US Patent:
    20160022825, Jan 28, 2016
  • Filed:
    Feb 15, 2013
  • Appl. No.:
    14/378813
  • Inventors:
    - Athens GA, US
    Sean M. Marrache - Athens GA, US
  • Assignee:
    UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. - Athens GA
  • International Classification:
    A61K 47/48
    A61K 31/355
    G01N 33/58
    A61K 31/12
    A61K 49/00
    A61K 31/416
    A61K 31/06
  • Abstract:
    Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more.

  • Generation Of Functional Dendritic Cells

    view source
  • US Patent:
    20150374714, Dec 31, 2015
  • Filed:
    Feb 11, 2014
  • Appl. No.:
    14/767063
  • Inventors:
    - Athens GA, US
    Sean Marrache - Portland OR, US
    Donald A. Harn - Athens GA, US
    Smanla Tundup - Downers Grove IL, US
  • International Classification:
    A61K 31/555
    C08G 63/08
    C12N 5/0784
    A61K 41/00
    A61K 47/48
  • Abstract:
    Nanoparticles containing a photosensitizer configured to generate a reactive oxygen species when exposed to an appropriate wavelength of light can be used to enhance immunogenicity of cancer cells, such as breast cancer cells. Such enhanced immunogenicity cancer cells, or supernatants thereof, can be used to activate dendritic cells or cause dendritic cells to produce INF-gamma. Nanoparticles having mitochondria-targeting moieties are more effective at enhancing the immunogenicity of the cancer cells, or causing the dendritic cells to produce IFN-gamma, than nanoparticle lacking mitochondria-targeting moieties or free photo sensitizer.
Get Report for Sean M Marrache from Concord, CA, age ~39
Control profile